Industry overview of cannabis and hemp companies with revenue and partnership details
Summary
The passage provides commercial financial metrics and partnership information for several cannabis‑related firms. It contains no references to high‑ranking officials, government agencies, or illicit a GTI reports $41.7 M revenue with >300% YoY growth. Khiron Life Sciences entered a 50/50 JV with U.S. Dixie Brands for Latin American CBD cosmetics. Level Brands acquired CBD consumer brand cbdMD, gen
This document is from the House Oversight Committee Releases.
View Source CollectionPersons Referenced (2)
Tags
Related Documents (6)
Cowen report highlights strong EBITDA margins and growth forecasts for CBD companies Charlotte’s Web and CV Sciences
The passage provides financial performance data and growth projections for publicly traded cannabis firms, but it does not link any high‑ranking officials, government agencies, or controversial action Charlotte’s Web and CV Sciences report EBITDA margins above 30% in the most recent quarter. Charlotte’s Web projected 2018 revenue of $65‑80 million and 2019 revenue of $120‑170 million. Analysts exp
Cannabis Investment Report – Projected International Legal Market Values (Dec 2017)
The passage provides market size estimates for legal cannabis markets worldwide. It contains no references to political figures, government agencies, financial misconduct, or illicit flows. While it c Lists projected market values for 20+ countries based on 20% penetration and spending estimates. Sources data from Ackrell Capital, a FINRA‑registered firm. Includes adult population and average mont
Ackrell Capital Cannabis Company Financial Metrics Table
The document is a plain financial summary of cannabis companies listed on the Canadian Securities Exchange with no mention of influential actors, misconduct, or controversial transactions. It offers n Provides market cap, revenue, EBITDA, and valuation multiples for dozens of cannabis firms. Includes percentages of stock price below enterprise value. No names of political figures, government agenc
Cannabis Company Valuation Table from Cowen Report (Feb 2019)
The passage is a plain financial data table listing market metrics for cannabis companies. It contains no references to high‑profile individuals, government actions, or alleged misconduct, offering no Provides enterprise values, revenues, and price metrics for dozens of cannabis firms. Cites Thomson Reuters and Cowen as sources. Dated February 25, 2019, with no contextual commentary.
Industry analysis of cannabis-derived drug Epidiolex and consumer market opportunities
The passage provides a generic market overview and product strategy for cannabis-derived pharmaceuticals, mentioning no high‑profile individuals, government officials, or illicit financial flows. It l Epidiolex is a CBD‑based drug under FDA review, not yet approved. Approval would require rescheduling under the Controlled Substances Act. Identified market opportunities: health‑wellness brands, e‑c
Ackrell Capital Cannabis Investment Report (Dec 2017) – Canadian Stock Market Comparison
The document is a routine market analysis with no mention of high‑profile individuals, government agencies, or controversial transactions. It provides generic data on exchange listings and financial c Shows that >10% of Canadian Securities Exchange listings are cannabis‑related. Compares market size and median company values across TSX, TSXV, and CSE. Outlines listing and governance requirements f
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.